Seminars in Hematology
Volume 44 , Pages S12-S15 , April 2007

Deferasirox (Exjade®, ICL670) Preclinical Overview

  • Hanspeter Nick

      Affiliations

    • Corresponding Author InformationAddress correspondence to Hanspeter Nick, PhD, Novartis Pharma AG, Lichtstrasse 35, CH-4002 Basel, Switzerland.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0037-1963(07)00056-X

doi: 10.1053/j.seminhematol.2007.03.005

Seminars in Hematology
Volume 44 , Pages S12-S15 , April 2007

Article Tools

* Image Usage & Resolution